MannKind Corporation to Participate in BTIG Virtual Biotechnology Conference 2020

Rhea-AI Summary

MannKind Corporation (Nasdaq: MNKD) announced that CEO Michael Castagna will present at the BTIG Virtual Biotechnology Conference on August 11, 2020, at 2:00 pm ET. The live webcast will be accessible via the company's website, with a replay available for 14 days after the event. MannKind focuses on inhaled therapeutic products for diabetes and orphan lung diseases, with its flagship product, Afrezza® (inhaled insulin), being the only FDA-approved inhaled ultra-rapid-acting mealtime insulin available in the U.S.

WESTLAKE VILLAGE, Calif., Aug. 07, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diabetes and orphan lung diseases, announced today that its Chief Executive Officer, Michael Castagna, PharmD, will participate in a Fireside Chat at the BTIG Virtual Biotechnology Conference 2020 on Tuesday, August 11, 2020 at 2:00 pm (ET). Interested parties can access a link to the live webcast of the presentation from the Events & Presentations section of the Company's website at http://www.mannkindcorp.com. The webcast replay will remain available for 14 days following the live presentation.

About MannKind Corporation

MannKind Corporation (NASDAQ: MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and orphan lung diseases. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company’s first FDA-approved product and the only inhaled ultra rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S. For further information, visit www.mannkindcorp.com.

Company Contact:
818-661-5000
ir@mannkindcorp.com

FAQ

When will MannKind Corporation's CEO present at the BTIG Virtual Biotechnology Conference?

CEO Michael Castagna will present on August 11, 2020, at 2:00 pm ET.

How can I access the webcast for MannKind Corporation's presentation?

The live webcast can be accessed from the Events & Presentations section of MannKind's website.

What is MannKind Corporation known for?

MannKind Corporation focuses on developing inhaled therapeutic products, primarily for diabetes and orphan lung diseases.

What is Afrezza and why is it significant?

Afrezza is MannKind's FDA-approved inhaled insulin, recognized as the only inhaled ultra-rapid-acting mealtime insulin in the U.S.

How long will the webcast replay of MannKind's presentation be available?

The replay of the webcast will be available for 14 days following the live presentation.